Senores Pharmaceuticals Ltd
Fundamental Score
Senores Pharmaceuticals Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of SENORES across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Robust Profit Growth (152.18%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.
Strong Revenue Growth (60.75%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.
Conservative Debt Levels (D/E: 0.30)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Strong Interest Coverage (5.77x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
3 factors identified
Premium Valuation Risk (P/E: 42.68x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations. Consider entry timing carefully.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
Financial Statements
Comprehensive financial data for Senores Pharmaceuticals Ltd
About SENORES
Business Overview
Senores Pharmaceuticals Limited develops, manufactures, sells, and trades in pharmaceutical and allied products in India, the United States, the United Kingdom, Canada, and internationally. It offers pharmaceutical solutions, such as analgesic/antipyretic, anesthetics and allied products, antibacterial/antibiotic, antiviral, antifungal, antioxidants, antineoplastic, blood line, cardiovascular, neurology, antacid, and vitamin and mineral preparation solutions; and analgesic/anti-inflammatory/antipyretic, anti-diabetic, antimalarial, neutral supplements, and urinary tract generics, as well as management and consultancy services. The company was incorporated in 2017 and is based in Ahmedabad, India.
Company Details
Key Leadership
SENORES Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Senores Pharmaceuticals Ltd (SENORES)?
As of 06 Feb 2026, 10:15 am IST, Senores Pharmaceuticals Ltd (SENORES) is currently trading at ₹825.30. The stock has a market capitalization of ₹3.72K (Cr).
Is SENORES share price Overvalued or Undervalued?
SENORES is currently trading at a P/E ratio of 42.68x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Overvalued against its sector peers.
What factors affect the Senores Pharmaceuticals Ltd share price?
Key factors influencing SENORES's price include its quarterly earnings growth (Sales Growth: 60.75%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Senores Pharmaceuticals Ltd a good stock for long-term investment?
Senores Pharmaceuticals Ltd shows a 5-year Profit Growth of N/A% and an ROE of 11.82%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.30 before investing.
How does Senores Pharmaceuticals Ltd compare with its industry peers?
Senores Pharmaceuticals Ltd competes with major peers in the Pharmaceuticals. Investors should compare SENORES's P/E of 42.68x and ROE of 11.82% against the industry averages to determine its competitive standing.
What is the P/E ratio of SENORES and what does it mean?
SENORES has a P/E ratio of 42.68x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹43 for every ₹1 of annual earnings.
How is SENORES performing according to Bull Run's analysis?
SENORES has a Bull Run fundamental score of 38.9/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does SENORES belong to?
SENORES operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Senores Pharmaceuticals Ltd.
What is Return on Equity (ROE) and why is it important for SENORES?
SENORES has an ROE of 11.82%, which shows decent profitability but room for improvement. Return on Equity measures how efficiently Senores Pharmaceuticals Ltd generates profits from shareholders' equity.
How is SENORES's debt-to-equity ratio and what does it indicate?
SENORES has a debt-to-equity ratio of 0.30, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is SENORES's dividend yield and is it a good dividend stock?
SENORES offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has SENORES grown over the past 5 years?
SENORES has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in SENORES and why does it matter?
Promoters hold 45.80% of SENORES shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is SENORES's market capitalization category?
SENORES has a market capitalization of ₹3718 crores, placing it in the Small-cap category.
How volatile is SENORES stock?
SENORES has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for SENORES?
SENORES has a 52-week high of ₹N/A and low of ₹N/A.
What is SENORES's operating profit margin trend?
SENORES has a 5-year average Operating Profit Margin (OPM) of N/A%, indicating the company's operational efficiency.
How is SENORES's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 60.75% and YoY Profit Growth of 152.18%.
What is the institutional holding pattern in SENORES?
SENORES has FII holding of 4.28% and DII holding of 8.62%. Significant institutional holding often suggests professional confidence in the stock.